Raffael Kurek

3.0k total citations · 1 hit paper
39 papers, 2.2k citations indexed

About

Raffael Kurek is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Raffael Kurek has authored 39 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Raffael Kurek's work include Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). Raffael Kurek is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). Raffael Kurek collaborates with scholars based in Germany, United States and Spain. Raffael Kurek's co-authors include D. Wallwiener, Patricia S. Steeg, Tanja Fehm, Karl Sotlar, Seth M. Steinberg, Andreas M. Stark, Robert J. Weil, Diane Palmieri, Julie L. Bronder and Susan E. Clare and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Raffael Kurek

39 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology profile →

Peers

Raffael Kurek

ONCOL

PRM

IMMUN

Bungo Furusato United States

Akos Czibere United States

Waldemar Wilczak Germany

Lynn Cawkwell United Kingdom

Richard Sesboüé France

Ana C. Garrido-Castro United States

María J. Pajares Spain

Jeffrey H. Hager United States

Bo Baldetorp Sweden

Suki Kang South Korea

Bungo Furusato United States

Raffael Kurek

759 ×0.8

ONCOL

1.1k ×1.2

1.4k ×1.9

PRM

618 ×1.1

204 ×0.8

IMMUN

Citations per year, relative to Raffael Kurek Raffael Kurek (= 1×) peers Bungo Furusato

Countries citing papers authored by Raffael Kurek

Since Specialization

Citations

This map shows the geographic impact of Raffael Kurek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raffael Kurek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raffael Kurek more than expected).

Fields of papers citing papers by Raffael Kurek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raffael Kurek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raffael Kurek. The network helps show where Raffael Kurek may publish in the future.

Co-authorship network of co-authors of Raffael Kurek

This figure shows the co-authorship network connecting the top 25 collaborators of Raffael Kurek. A scholar is included among the top collaborators of Raffael Kurek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raffael Kurek. Raffael Kurek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paz‐Ares, Luis, Nick Thatcher, David R. Spigel, et al.. (2018). Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis. Thrombosis Research. 167. 50–56. 6 indexed citations

Genova, Carlo, Mark A. Socinski, Rebecca R. Hozak, et al.. (2017). EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. Journal of Thoracic Oncology. 13(2). 228–236. 10 indexed citations

Smith, David C., John D. Powderly, James J. Lee, et al.. (2016). Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 78(2). 271–280. 3 indexed citations

Paz‐Ares, Luis, Mark A. Socinski, Javad Shahidi, et al.. (2016). Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Annals of Oncology. 27(8). 1573–1579. 54 indexed citations

Thatcher, Nick, Fred R. Hirsch, Alexander Luft, et al.. (2015). Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. The Lancet Oncology. 16(7). 763–774. 331 indexed citations breakdown →

Schiller, Joan H., Joachim von Pawel, Philipp Schütt, et al.. (2010). Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(12). 1977–1985. 45 indexed citations

Rao, Sheela, Naureen Starling, David Cunningham, et al.. (2010). Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Annals of Oncology. 21(11). 2213–2219. 86 indexed citations

Becker, Sven, Erich Solomayer, René Hornung, et al.. (2009). Optimal treatment for patients with ectopic pregnancies and a history of fertility-reducing factors. Archives of Gynecology and Obstetrics. 283(1). 41–45. 15 indexed citations

Marmé, Alexander, H Zimmermann, Gerhard Moldenhauer, et al.. (2008). Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas. International Journal of Cancer. 123(9). 2048–2056. 29 indexed citations

10.

Neubauer, Hans, Susan E. Clare, Wojciech Woźny, et al.. (2008). Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Research. 10(5). R85–R85. 97 indexed citations

11.

Palmieri, Diane, Julie L. Bronder, Jeanne M. Herring, et al.. (2007). Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain. Cancer Research. 67(9). 4190–4198. 267 indexed citations

12.

Bonin, Michael, Susan E. Clare, Kay Nieselt, et al.. (2006). Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis. Cancer Research. 66(10). 5278–5286. 191 indexed citations

13.

Hu, Lijuan, et al.. (2006). Expression of Human Endogenous Gammaretroviral Sequences in Endometriosis and Ovarian Cancer. AIDS Research and Human Retroviruses. 22(6). 551–557. 21 indexed citations

14.

Aydeniz, B., et al.. (2006). The critical path method to analyze and modify OR‐workflow: Integration of an image documentation system. Minimally Invasive Therapy & Allied Technologies. 15(3). 177–186. 5 indexed citations

15.

Neubauer, Hans, Susan E. Clare, Raffael Kurek, et al.. (2006). Breast cancer proteomics by laser capture microdissection, sample pooling, 54‐cm IPG IEF, and differential iodine radioisotope detection. Electrophoresis. 27(9). 1840–1852. 57 indexed citations

16.

Fehm, Tanja, Sven Becker, B. Krämer, et al.. (2005). Influence of tumor biological factors on tumor cell dissemination in primary breast cancer.. PubMed. 24(6). 4211–6. 18 indexed citations

17.

Fehm, Tanja, W. Jäger, S. Kraemer, et al.. (2005). Changes of serum HER2 status during clinical course of metastatic breast cancer patients.. PubMed. 24(6). 4205–10. 16 indexed citations

18.

Huober, Jens, U. Krainick‐Strobel, Raffael Kurek, & D. Wallwiener. (2004). Neoadjuvant Endocrine Therapy in Primary Breast Cancer. Clinical Breast Cancer. 5(5). 341–347. 13 indexed citations

19.

Tolosa, Eva, Weijie Li, Yoshiyuki Yasuda, et al.. (2003). Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. Journal of Clinical Investigation. 112(4). 517–526. 104 indexed citations

20.

Tunn, U. W., Nicholas Bruchovsky, H. Renneberg, J.M. Wolff, & Raffael Kurek. (2000). Intermittierende Androgendeprivation. Der Urologe. 39(1). 9–13. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact